CD274 and neoplasm: Successful antitumour immune responses following PD-1/PD-L1 blockade require reactivation and clonal proliferation of tumour-specific T cells in the tumour microenvironment (TME), and the differences in the effects of ICIs can be partially attributed to the heterogeneity of the TME [6, 7].